Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Valtech Cardio Ltd.

Division of Edwards Lifesciences Corp.
www.valtechcardio.com

Latest From Valtech Cardio Ltd.

Market Brief: Innovation Will Drive 13% Growth In Global Transcatheter Mitral Valve Repair Market by 2023, Outpacing Growth Of TAVR

The transcatheter heart valve management products market will reach $6.7bn by 2023, driven by the rising prevalence of heart disease. Transcatheter aortic valve replacement (TAVR) procedures lead the market, but innovation and rising competition, including from companies in China and India, will fuel double-digit growth in the much smaller mitral valve repair market, dominated by Abbott's MitraClip.

Market Intelligence Innovation

Edwards Adds To Wide Range Of Approaches To Mitral Repair

Harpoon is a minimally invasive surgery device that complements Edwards pipeline of transcatheter mitral and septal valve repair and replacement technologies, which now includes at least six technologies at various stages of development, and is one of the company's top R&D priorities.

M & A Cardiology

Starts & Stops: Valve Repair And Replacement Tech Continues To Attract R&D Investment

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial announcements, initiations, completions, and suspensions each month. This month's edition, covering the period between mid-July and mid-August, includes trials from the biggest medtech players, some start-ups, and companies of every size in between.

Clinical Trials Starts & Stops

Abbott Launches Feasibility Trial Of Tricuspid Version Of MitraClip

The TRILUMINATE trial will evaluate safety and effectiveness of its Tricuspid Valve Repair System for treating symptomatic moderate-to-severe tricuspid regurgitation. The device is similar to Abbott's successful MitraClip catheter-based device for treating mitral regurgitation.

Clinical Trials Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Edwards Lifesciences Corp.
  • Senior Management
  • Amir Gross, CEO
    Tal Reich, COO
    Ilia Hariton, PhD, VP, R&D
    Nitza Shoham, VP, Clinical & RA
    Tomer Druker, VP, Finance & HR
  • Contact Info
  • Valtech Cardio Ltd.
    Phone: (972) 3535959
    3 Ariel Sharon Ave.
    Or-Yehuda, 60376
    Israel
UsernamePublicRestriction

Register